Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333313 | 0.87 | SLC6A4 (0.41) | GAARCE1IKBKBBRAFALDH1A1 | |
| SCHEMBL4531281 | 0.84 | GAA (0.46) | GAARCE1IKBKBBRAFALDH1A1 | |
| SCHEMBL18659791 | 0.81 | GAA (0.53) | GAARCE1IKBKBBRAFALDH1A1 | |
| SCHEMBL8703777 | 0.80 | GAA (0.56) | GAARCE1IKBKBBRAFALDH1A1 | |
| SCHEMBL13719144 | 0.80 | XIAP (0.49) | ALDH1A1TDP1MAPTCARM1PRMT6 | |
| SCHEMBL2285909 | 0.80 | GAA (0.69) | GAARCE1IKBKBBRAFALDH1A1 | |
| SCHEMBL9252743 | 0.78 | LTA4H (0.55) | LTA4H | |
| SCHEMBL5078385 | 0.78 | CYP1A2 (0.51) | GAARCE1IKBKBBRAFALDH1A1 | |
| SCHEMBL4575613 | 0.78 | SLC6A4 (0.48) | CYP2C9PTGS1SLC6A4 | |
| SCHEMBL1270588 | 0.78 | GAA (0.67) | GAARCE1IKBKBBRAFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | GAA 2596/4885RCE1 1253/4885IKBKB 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.